Exo’s approach seeks to overcome these challenges with its novel exosite inhibitors that disrupt STING-mediated TBK1 activation while avoiding the beneficial functions of the kinase on viral ...

“Exo’s data look very promising, particularly the targeting of both interferon-beta and NF-kB pathways by your molecule,” said Mary K. Crow, M.D., Physician-in-Chief Emeritus at Hospital for ...

CAMBRIDGE, Mass., November 18, 2024--Exo presented a late-breaking poster on its preclinical program targeting the TBK1/STING interaction of the cGAS-STING pathway at the ACR 2024.

CAMBRIDGE, Mass., June 20, 2024--Exo Therapeutics presents on its preclinical program targeting TBK1/STING interaction of the cGAS-STING pathway at FOCIS 2024.

Exo Therapeutics Inc. has presented data on its preclinical program targeting TBK1/STING interaction of the cGAS-STING pathway. The company has identified potent, selective exosite-targeted TBK1/STING ...